Zika Fever disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ZKF001 MIFTS: 47	Zika Fever Categories: Blood diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Zika Fever

MalaCards integrated aliases for Zika Fever:

Name: Zika Fever ¹² ⁵² ¹⁵

Zika Virus Infection ⁵² ⁵⁸ ³ ⁴³ ⁷¹

Zika Virus Disease ¹² ⁵² ⁵⁸

Zika Virus ⁷⁴ ⁴²

Characteristics:

Orphanet epidemiological data:

⁵⁸

zika virus disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Brazil); Age of onset: All ages; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Neuronal diseases Reproductive diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Certain infectious and parasitic diseases

Arthropod-borne viral fevers and viral haemorrhagic fevers

Other mosquito-borne viral fevers

Other specified mosquito-borne viral fevers

Orphanet: ⁵⁸

Rare infectious diseases

External Ids:

Disease Ontology ¹² DOID:0060478

MeSH ⁴³ D000071243

ICD10 ³² A92.8

ICD10 via Orphanet ³³ U06

Orphanet ⁵⁸ ORPHA448237

UMLS ⁷¹ C0276289

Sources

Summaries for Zika Fever

MedlinePlus : ⁴² Zika is a virus that is spread mostly by mosquitoes. A pregnant mother can pass it to her baby during pregnancy or around the time of birth. It can spread through sexual contact. There have also been reports that the virus has spread through blood transfusions. There have been outbreaks of Zika virus in the United States, Africa, Southeast Asia, the Pacific Islands, parts of the Caribbean, and Central and South America. Most people who get the virus do not get sick. One in five people do get symptoms, which can include a fever, rash, joint pain, and conjunctivitis (pinkeye). Symptoms are usually mild, and start 2 to 7 days after being bitten by an infected mosquito. A blood test can tell whether you have the infection. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking acetaminophen might help. Zika can cause microcephaly (a serious birth defect of the brain) and other problems in babies whose mothers were infected while pregnant. The Centers for Disease Control and Prevention recommends that pregnant women do not travel to areas where there is a Zika virus outbreak. If you do decide to travel, first talk to your doctor. You should also be careful to prevent mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary : Zika Fever, also known as zika virus infection, is related to encephalitis and west nile encephalitis, and has symptoms including fever, rash and headaches. An important gene associated with Zika Fever is CD40LG (CD40 Ligand), and among its related pathways/superpathways is Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics. The drugs Hydroxychloroquine and Ivermectin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are arthritis and microcephaly

Disease Ontology : ¹² A viral infectious disease that has material basis in Zika virus, which is transmitted by Aedes aegypti mosquitoes and targets neural progenitor cells and neuronal cells in all stages of maturity and has symptom fever, has symptom rash, has symptom headaches and has symptom joint pain.

NIH Rare Diseases : ⁵² Zika virus infection is spread to people primarily through the bite of an infected mosquito. Zika virus can also be spread from a pregnant mother to her child and through sexual contact with an affected partner. Cases of Zika virus transmission via blood transfusion have also been reported. Zika virus outbreaks are currently occurring in many countries. The illness associated with Zika virus infection is usually mild, with symptoms lasting for several days to a week. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). However, research has suggested an association between Zika virus infection and Guillain-Barre syndrome (GBS) in a small percentage of cases. Zika virus infection during pregnancy can cause adverse pregnancy outcomes, including microcephaly and other serious brain defects. The full range of health problems associated with Zika virus infection during pregnancy is currently being studied. No vaccine currently exists to prevent Zika virus infection, but there are still ways to protect oneself. The CDC recommends that pregnant women consider postponing travel to Zika-affected areas. People living in or traveling to areas where Zika virus is found should take steps to prevent mosquito bites . Those who have traveled to Zika-affected areas may wish to take steps to prevent sexual transmission of the Zika virus.

CDC : ³ Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). These mosquitoes bite during the day and night. Zika can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause certain birth defects. There is no vaccine or medicine for Zika.

Wikipedia : ⁷⁴ Zika virus (ZIKV) (pronounced /ˈziːkə/ or /ˈzɪkə/) is a member of the virus family Flaviviridae. It is... more...

Sources

Related Diseases for Zika Fever

Diseases related to Zika Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)

#	Related Disease	Score	Top Affiliating Genes
1	encephalitis	31.3	ERVW-1 CD40LG CD209
2	west nile encephalitis	30.1	PRNT CD40LG
3	measles	29.9	STAT2 IFNAR1 CD40LG CD209
4	asymptomatic dengue	29.8	SENP8 PRNT CD40LG
5	acalculous cholecystitis	29.8	SENP8 CD40LG
6	dengue hemorrhagic fever	29.8	STAT2 IFNAR1 CD40LG CD209
7	west nile fever	29.7	PRNT ERVW-1 CD40LG CD209
8	ebola hemorrhagic fever	29.7	SCARA3 ERVW-1 CD40LG
9	dengue shock syndrome	29.6	SENP8 ERVW-1 CD40LG CD209
10	st. louis encephalitis	29.3	SENP8 PRNT ERVW-1 CD40LG
11	dengue disease	29.3	SENP8 PRNT ERVW-1 CD40LG CD209
12	viral infectious disease	29.3	STAT2 IFNAR1 ERVW-1 CD40LG CD209
13	yellow fever	28.9	SENP8 PRNT IFNAR1 FGA
14	zika virus congenital syndrome	12.8
15	torch syndrome	11.3
16	hydrocephalus, congenital, 1	10.7
17	alkuraya-kucinskas syndrome	10.5
18	congenital amyoplasia	10.5
19	toxoplasmosis	10.5
20	glioblastoma multiforme	10.4
21	hydrocephalus	10.4
22	syphilis	10.4
23	tick-borne encephalitis	10.4
24	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus	10.4
25	lissencephaly	10.4
26	neuroblastoma	10.4
27	stomatitis	10.4
28	cytokine deficiency	10.3
29	alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity	10.3
30	phlebotomus fever	10.3	PRNT CD40LG
31	autoimmune disease	10.3
32	neural tube defects	10.3
33	cerebellar hypoplasia	10.3
34	infertility	10.3
35	acute disseminated encephalomyelitis	10.3
36	transverse myelitis	10.3
37	primary microcephaly	10.3
38	sensorineural hearing loss	10.3
39	demyelinating polyneuropathy	10.3
40	placenta disease	10.3
41	chikungunya	10.3
42	polymicrogyria with or without vascular-type ehlers-danlos syndrome	10.2
43	middle east respiratory syndrome	10.2
44	male infertility	10.2
45	cerebral palsy	10.2
46	purpura	10.2
47	polymicrogyria	10.2
48	pachygyria	10.2
49	yemenite deaf-blind hypopigmentation syndrome	10.2
50	visual epilepsy	10.2

Graphical network of the top 20 diseases related to Zika Fever:

Sources

Symptoms & Phenotypes for Zika Fever

Human phenotypes related to Zika Fever:

⁵⁸ (show all 34)

#	Description	Orphanet Frequency
1	arthritis ⁵⁸	Frequent (79-30%)
2	microcephaly ⁵⁸	Very rare (<4-1%)
3	vomiting ⁵⁸	Occasional (29-5%)
4	fever ⁵⁸	Frequent (79-30%)
5	edema ⁵⁸	Occasional (29-5%)
6	skin rash ⁵⁸	Very frequent (99-80%)
7	pruritus ⁵⁸	Frequent (79-30%)
8	arthralgia ⁵⁸	Frequent (79-30%)
9	myalgia ⁵⁸	Frequent (79-30%)
10	intrauterine growth retardation ⁵⁸	Very rare (<4-1%)
11	thrombocytopenia ⁵⁸	Very rare (<4-1%)
12	lens subluxation ⁵⁸	Very rare (<4-1%)
13	iris coloboma ⁵⁸	Very rare (<4-1%)
14	conjunctivitis ⁵⁸	Frequent (79-30%)
15	meningitis ⁵⁸	Very rare (<4-1%)
16	headache ⁵⁸	Frequent (79-30%)
17	subcutaneous hemorrhage ⁵⁸	Very rare (<4-1%)
18	encephalitis ⁵⁸	Very rare (<4-1%)
19	spontaneous abortion ⁵⁸	Very rare (<4-1%)
20	optic disc hypoplasia ⁵⁸	Very rare (<4-1%)
21	wrist swelling ⁵⁸	Occasional (29-5%)
22	abnormality of the optic disc ⁵⁸	Very rare (<4-1%)
23	increased circulating igm level ⁵⁸	Frequent (79-30%)
24	macular atrophy ⁵⁸	Very rare (<4-1%)
25	maculopapular exanthema ⁵⁸	Very frequent (99-80%)
26	retinal pigment epithelial mottling ⁵⁸	Very rare (<4-1%)
27	ankle swelling ⁵⁸	Occasional (29-5%)
28	abnormality of the cerebrospinal fluid ⁵⁸	Frequent (79-30%)
29	chorioretinal atrophy ⁵⁸	Very rare (<4-1%)
30	myelitis ⁵⁸	Very rare (<4-1%)
31	acute demyelinating polyneuropathy ⁵⁸	Very rare (<4-1%)
32	absent foveal reflex ⁵⁸	Very rare (<4-1%)
33	transient hearing impairment ⁵⁸	Occasional (29-5%)
34	congenital intracerebral calcification ⁵⁸	Very rare (<4-1%)

Symptoms:

¹²

• fever
• rash

• headaches
• joint pain

Sources

Drugs & Therapeutics for Zika Fever

Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Hydroxychloroquine

Approved

Phase 3

118-42-3

3652

Synonyms:

(+-)-Hydroxychloroquine

(±)-hydroxychloroquine

118-42-3

2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol

2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol

2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol

2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol

2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol

2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol

2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol

5-22-10-00280 (Beilstein Handbook Reference)

747-36-4 (sulfate (1:1) salt)

7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline

7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline

7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline

7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline

7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline

7-chloro-4-(4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline

7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline

7-chloro-4-(4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline

7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline

7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline

7-chloro-4-[4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline

7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline

7-chloro-4-[4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline

7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline

7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline

AC1L1GEW

Axemal

BRN 0253894

C07043

C18H26ClN3O

CHEMBL1535

CID3652

D08050

DB01611

DivK1c_000942

Dolquine

EINECS 204-249-8

Ercoquin

Gen-Hydroxychloroquine 200mg Tablets

HCQ

Hidroxicloroquina

Hidroxicloroquina [inn-spanish]

Hidroxicloroquina [INN-Spanish]

HMS502P04

Hydroxychlorochin

Hydroxychloroguine

hydroxychloroquine

Hydroxychloroquine

Hydroxychloroquine (INN)

Hydroxychloroquine [INN:BAN]

Hydroxychloroquine sulfate

Hydroxychloroquine sulfate (1:1) salt

Hydroxychloroquine Sulfate (1:1) Salt

Hydroxychloroquinum

Hydroxychloroquinum [inn-latin]

Hydroxychloroquinum [INN-Latin]

IDI1_000942

Idrossiclorochina

Idrossiclorochina [dcit]

Idrossiclorochina [DCIT]

KBio1_000942

LS-66614

MolPort-003-847-792

NCGC00159483-02

NINDS_000942

NSC4375

Oxichlorochine

Oxichlorochinum

Oxichloroquine

Oxychlorochin

Oxychloroquine

PlaqueN/A

Plaquenil

Polirreumin

Polirreumin (TN)

Quensyl

SPBio_001116

Spectrum2_001238

Spectrum5_001697

ST072188

UNII-4QWG6N8QKH

WIN 1258

Ivermectin

Approved, Investigational, Vet_approved

Phase 3

70288-86-7

6474909

Synonyms:

(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside

71827-03-7

AB00513813

AC1MJ4GR

AC1N7O27

BPBio1_000322

BRD-K24652731-001-02-7

BSPBio_000292

CHEMBL341047

CID11957587

CID4330618

CID6321424

CID6419971

CID6427057

EU-0100693

FT-0082656

HMS1568O14

HMS2089M09

I 8898

I8898_SIGMA

Ivermectin

IVERMECTIN

Ivermectina

Ivermectine

Ivermectinum

Lopac0_000693

MK-933

MLS001333247

MLS001333248

MLS002153248

MolPort-006-394-715

NCGC00094047-01

NCGC00094047-02

NCGC00094047-03

Prestwick_516

Prestwick2_000156

Prestwick3_000156

S1351_Selleck

SMR000857211

Anti-Infective Agents

Phase 3

Antiparasitic Agents

Phase 3

Antiprotozoal Agents

Phase 3

Antirheumatic Agents

Phase 3

Antimalarials

Phase 3

Immunologic Factors

Phase 2

Aluminum sulfate

Approved

Phase 1

10043-01-3

Aluminum hydroxide

Approved, Investigational

Phase 1

21645-51-2

Immunoglobulins, Intravenous

Phase 1

Rho(D) Immune Globulin

Phase 1

gamma-Globulins

Phase 1

Immunoglobulin G

Phase 1

Antibodies, Blocking

Phase 1

Antibodies

Phase 1

Immunoglobulins

Phase 1

Antibodies, Monoclonal

Phase 1

Vaccines

Phase 1

Pharmaceutical Solutions

Phase 1

Interventional clinical trials:

(show top 50) (show all 67)

#	Name	Status	NCT ID	Phase	Drugs
1	Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study	Recruiting	NCT03037164	Phase 3
2	Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial	Recruiting	NCT04391127	Phase 3	Hydroxychloroquine;Ivermectin;Placebo
3	VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents	Completed	NCT03110770	Phase 2
4	A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region	Completed	NCT03014089	Phase 1
5	A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults	Completed	NCT02937233	Phase 1
6	VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults	Completed	NCT02996461	Phase 1
7	Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers	Completed	NCT03624946	Phase 1
8	A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years	Completed	NCT03425149	Phase 1
9	Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults	Completed	NCT02809443	Phase 1
10	Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers	Completed	NCT02996890	Phase 1
11	Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults	Completed	NCT02887482	Phase 1
12	Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults	Completed	NCT03611946	Phase 1
13	Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers	Completed	NCT03443830	Phase 1	Tyzivumab
14	VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults	Completed	NCT02840487	Phase 1
15	Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects	Completed	NCT02952833	Phase 1	Saline
16	A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects	Completed	NCT02963909	Phase 1
17	Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine	Completed	NCT03055000	Phase 1
18	Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B)	Completed	NCT03776786	Phase 1
19	Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP	Recruiting	NCT04033068	Phase 1
20	Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients	Recruiting	NCT03776695	Phase 1
21	A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers Given as a Standalone Vaccine or Co-administered With the Chikungunya Virus (CHIKV) Candidate Vaccine ChAdOx1 Chik	Recruiting	NCT04015648	Phase 1
22	A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults	Active, not recruiting	NCT04064905	Phase 1
23	A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years	Active, not recruiting	NCT03343626	Phase 1	Placebo
24	Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area	Active, not recruiting	NCT03008122	Phase 1
25	Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.	Unknown status	NCT03161444
26	Persistence of Zika Virus in Semen After Acute Infection	Unknown status	NCT02733796
27	Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016	Unknown status	NCT02810210
28	Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016	Unknown status	NCT02916732
29	Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome	Unknown status	NCT03227601
30	Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF	Unknown status	NCT03255369
31	Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine	Completed	NCT03158233
32	The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01)	Completed	NCT02831699
33	Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA	Completed	NCT03776903
34	Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation.	Completed	NCT03679728
35	Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection	Completed	NCT02979938
36	Rash Accompanied by Three or More Dengue-like Symptoms During Pregnancy and Microcephaly: Case-control Study	Completed	NCT02741882
37	Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors	Completed	NCT02794181
38	Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome	Completed	NCT03330600
39	Pilot Study to Detect Zika Virus in Sperm	Completed	NCT02874456
40	Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia	Completed	NCT03206541
41	Randomized Trial to Assess Parental Response to Different Presentations of Vaccination Data for Schools and Child Care Centers	Completed	NCT02957344
42	TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes"	Completed	NCT02818413
43	Spatial Repellent Products for Control of Vector-borne Diseases - Dengue	Completed	NCT03553277
44	Pilot Study to Detect DENGUE Virus in Sperm.	Completed	NCT03612609
45	Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy	Recruiting	NCT02943304
46	Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r	Recruiting	NCT01099852
47	Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy	Recruiting	NCT03393286
48	World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia	Recruiting	NCT03631719
49	The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy	Recruiting	NCT04118738
50	Neuro-COVID-19: Neurological Complications of COVID-19	Recruiting	NCT04418609

Search NIH Clinical Center for Zika Fever

Cochrane evidence based reviews: zika virus infection

Sources

Genetic Tests for Zika Fever

Sources

Anatomical Context for Zika Fever

MalaCards organs/tissues related to Zika Fever:

⁴⁰

Brain, Testes, Eye, T Cells, Skin, Placenta, Fetal Brain

Sources

Publications for Zika Fever

Articles related to Zika Fever:

(show top 50) (show all 1430)

#	Title	Authors	PMID	Year
1	Characterization of Placental Infection by Zika Virus in Humans: A Review of the Literature. ⁶¹ ⁴²	Venceslau EM...Costa ML	32559805	2020
2	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. ⁴²	Lopez-Camacho C...Reyes-Sandoval A	32560145	2020
3	RIG-I Plays a Dominant Role in the Induction of Transcriptional Changes in Zika Virus-Infected Cells, which Protect from Virus-Induced Cell Death. ⁴²	Schilling M...Rehwinkel J	32560274	2020
4	Structure-activity relationship of flavonoid bifunctional inhibitors against Zika virus infection. ⁶¹	Zou M...Liu S	32272109	2020
5	Brain Iron Accumulation and the Formation of Calcifications After Developmental Zika Virus Infection. ⁶¹	Snyder-Keller A...Kramer LD	32483612	2020
6	The involvement of annexin A1 in human placental response to maternal Zika virus infection. ⁶¹	Molas RB...Oliani SM	32360947	2020
7	The P-MAPA immunomodulator partially prevents apoptosis induced by Zika virus infection in THP-1 cells. ⁶¹	Lima MC...Franca RFO	32484769	2020
8	7-Deaza-7-Fluoro-2'-C-Methyladenosine Inhibits Zika virus Infection and Viral-induced Neuroinflammation. ⁶¹	Del Sarto JL...Teixeira MM	32574688	2020
9	Forced Zika Virus Infection of Culex pipiens Leads to Limited Virus Accumulation in Mosquito Saliva. ⁶¹	Abbo SR...Pijlman GP	32575394	2020
10	Zika virus detection in amniotic fluid and Zika-associated birth defects. ⁶¹	Mercado M...Ospina ML	31954155	2020
11	A Single-Center Experience with a Pregnant Immigrant Population and Zika Virus Serologic Screening in New York City. ⁶¹	Merriam AA...Gyamfi-Bannerman C	31146294	2020
12	Experience in diagnosing congenital Zika syndrome in Brazilian children born to asymptomatic mothers. ⁶¹	Vianna RAO...Cardoso CAA	32165128	2020
13	Insecticide resistance, fitness and susceptibility to Zika infection of an interbred Aedes aegypti population from Rio de Janeiro, Brazil. ⁶¹	Dos Santos CR...Atella GC	32513248	2020
14	Zika virus infection in asymptomatic persons in Myanmar, 2018. ⁶¹	Ngwe Tun MM...Morita K	32043531	2020
15	T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine. ⁶¹	Wang R...An J	32556415	2020
16	Vesicular stomatitis virus and DNA vaccines expressing Zika virus nonstructural protein 1 (NS1) induce substantial but not sterilizing protection against Zika virus infection. ⁶¹	Li A...Li J	32554698	2020
17	A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques. ⁶¹	Lim SY...Whitney JB	32522808	2020
18	Performance of an Automated Zika IgG Immunoassay in the Detection of Zika IgG Specific Antibodies-A Validation Approach in Samples from Prevalence Areas and Non-Endemic Countries. ⁶¹	Laengin T...Riedel A	32521651	2020
19	A unique immune signature of serum cytokine and chemokine dynamics in patients with Zika virus infection from a tropical region in Southern Mexico. ⁶¹	Zuniga J...Emerging Infectious Diseases Clinical Research Network of Mexico (La Red)	32081772	2020
20	Neurological outcomes of congenital Zika syndrome in toddlers and preschoolers: a case series. ⁶¹	Pereira HVFS...Melo A	32199080	2020
21	Comparative analysis of a Thai congenital-Zika-syndrome-associated virus with a Thai Zika-fever-associated virus. ⁶¹	Jitsatja A...Smith DR	32474686	2020
22	Emergence of Zika virus infection in China. ⁶¹	Zhou CM...Yu XJ	32427996	2020
23	Malaria in the Pregnant Traveler. ⁶¹	McKinney KL...Gutman JR	32419013	2020
24	Long-term alterations in brain and behavior after postnatal Zika virus infection in infant macaques. ⁶¹	Raper J...Chahroudi A	32439858	2020
25	Discordant Zika Virus Findings in Twin Pregnancies Complicated by Antenatal Zika Virus Exposure: A Prospective Cohort. ⁶¹	Sobhani NC...Gaw SL	31773163	2020
26	Role of Prenatal Ultrasonography and Amniocentesis in the Diagnosis of Congenital Zika Syndrome: A Systematic Review. ⁶¹	Viens LJ...Meaney-Delman D	32282593	2020
27	Evolutionary analysis of the Musashi family: What can it tell us about Zika? ⁶¹	Caldas-Garcia GB...Bortolini MC	32422351	2020
28	Maternal Zika Virus (ZIKV) Infection following Vaginal Inoculation with ZIKV-Infected Semen in Timed-Pregnant Olive Baboons. ⁶¹	Gurung S...Myers DA	32188737	2020
29	Women's Awareness and Healthcare Provider Discussions about Zika Virus during Pregnancy, United States, 2016-2017. ⁶¹	Williams L...PRAMS Zika State Working Group	32310074	2020
30	Functional Outcomes among a Cohort of Children in Northeastern Brazil Meeting Criteria for Follow-Up of Congenital Zika Virus Infection. ⁶¹	Bertolli J...Peacock G	32228785	2020
31	The effects of Japanese encephalitis virus antibodies on Zika virus infection. ⁶¹	He X...Zhao W	32078028	2020
32	Basic insights into Zika virus infection of neuroglial and brain endothelial cells. ⁶¹	Mutso M...Mahalingam S	32375993	2020
33	Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening. ⁶¹	Chang CY...Ho TJ	32344649	2020
34	New Challenge for Zika Virus Infection: Human Reservoirs? ⁶¹	Campos GS...Sardi SI	32311307	2020
35	CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. ⁶¹	Wen J...Shresta S	32348763	2020
36	Modulation in phase and frequency of neural oscillations during epileptiform activity induced by neonatal Zika virus infection in mice. ⁶¹	Pinheiro DJLL...Faber J	32317689	2020
37	IL-27 signaling activates skin cells to induce innate antiviral proteins and protects against Zika virus infection. ⁶¹	Kwock JT...MacLeod AS	32270034	2020
38	Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype. ⁶¹	Leonhard SE...P Militao de Albuquerque MF	32339199	2020
39	Absence of Evidence of Zika Virus Infection in Cord Blood and Urine from Newborns with Congenital Abnormalities, Indonesia. ⁶¹	Putri ND...Aye Myint KS	32043460	2020
40	Schinus terebenthifolius Raddi extracts: from sunscreen activity toward protection of the placenta to Zika virus infection, new uses for a well-known medicinal plant. ⁶¹	Dos Santos Oliveira MB...Fonseca Goulart MO	32346222	2020
41	Dengue fever complicated by liver dysfunction due to possible co-infection with hepatitis E in a returning traveller from Cuba. ⁶¹	Antinori S...Zanchetta N	32172268	2020
42	Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study. ⁶¹	Burger-Calderon R...Harris E	31870907	2020
43	ZIKA Virus infection in pregnant women in French Guiana: More precarious-more at risk. ⁶¹	Hallet E...Nacher M	32208419	2020
44	Emerging and neglected zoonoses in transplant population. ⁶¹	Mrzljak A...Vilibic-Cavlek T	32257849	2020
45	Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. ⁶¹	Fernandez E...Diamond MS	32001822	2020
46	Zika virus infection studies with CD34+ hematopoietic and megakaryocyte-erythroid progenitors, red blood cells and platelets. ⁶¹	Roth H...Baylis SA	32086956	2020
47	Zika virus infection in chemosensory cells. ⁶¹	Ozdener MH...Sariyer IK	32144727	2020
48	IRE1α Promotes Zika Virus Infection via XBP1. ⁶¹	Kolpikova EP...Fink SL	32138181	2020
49	Vaccination with Aedes aegypti AgBR1 Delays Lethal Mosquito-Borne Zika Virus Infection in Mice. ⁶¹	Wang Y...Fikrig E	32218189	2020
50	Different populations of Aedes aegypti and Aedes albopictus (Diptera: Culicidae) from Central Africa are susceptible to Zika virus infection. ⁶¹	Kamgang B...Failloux AB	32203510	2020

Sources

Genes for Zika Fever

Genes related to Zika Fever (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CD40LG	CD40 Ligand	Protein Coding	6.63	DISEASES inferred ¹⁵
2	PRNT	Prion Locus LncRNA, Testis Expressed	RNA Gene	6.52	DISEASES inferred ¹⁵
3	DNAAF2	Dynein Axonemal Assembly Factor 2	Protein Coding	6.39	DISEASES inferred ¹⁵
4	AXL	AXL Receptor Tyrosine Kinase	Protein Coding	5.79	DISEASES inferred ¹⁵
5	CD209	CD209 Molecule	Protein Coding	5.55	DISEASES inferred ¹⁵
6	ERVW-1	Endogenous Retrovirus Group W Member 1, Envelope	Protein Coding	5.49	DISEASES inferred ¹⁵
7	BPHL	Biphenyl Hydrolase Like	Protein Coding	5.33	DISEASES inferred ¹⁵
8	TYRO3	TYRO3 Protein Tyrosine Kinase	Protein Coding	5.25	DISEASES inferred ¹⁵
9	FGA	Fibrinogen Alpha Chain	Protein Coding	5.22	DISEASES inferred ¹⁵
10	DDIT4L	DNA Damage Inducible Transcript 4 Like	Protein Coding	5.2	DISEASES inferred ¹⁵
11	STAT2	Signal Transducer And Activator Of Transcription 2	Protein Coding	5.09	DISEASES inferred ¹⁵
12	IFNAR1	Interferon Alpha And Beta Receptor Subunit 1	Protein Coding	5	DISEASES inferred ¹⁵
13	SENP8	SUMO Peptidase Family Member, NEDD8 Specific	Protein Coding	4.93	DISEASES inferred ¹⁵
14	SH2D3C	SH2 Domain Containing 3C	Protein Coding	4.87	DISEASES inferred ¹⁵
15	SCARA3	Scavenger Receptor Class A Member 3	Protein Coding	4.83	DISEASES inferred ¹⁵

Sources

Variations for Zika Fever

Sources

Expression for Zika Fever

Search GEO for disease gene expression data for Zika Fever.

Sources

Pathways for Zika Fever

Pathways related to Zika Fever according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics ⁶⁰ Show member pathways Inhibition of PKR ⁶⁵	9.98	STAT2 IFNAR1

Sources

GO Terms for Zika Fever

Cellular components related to Zika Fever according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cell surface	GO:0009986	9.02	TYRO3 FGA CD40LG CD209 AXL

Biological processes related to Zika Fever according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	viral entry into host cell	GO:0046718	9.58	TYRO3 CD209 AXL
2	JAK-STAT cascade	GO:0007259	9.51	STAT2 IFNAR1
3	leukocyte cell-cell adhesion	GO:0007159	9.49	CD40LG CD209
4	apoptotic cell clearance	GO:0043277	9.48	TYRO3 AXL
5	natural killer cell differentiation	GO:0001779	9.46	TYRO3 AXL
6	cellular response to interferon-alpha	GO:0035457	9.43	IFNAR1 AXL
7	vagina development	GO:0060068	9.37	TYRO3 AXL
8	secretion by cell	GO:0032940	9.32	TYRO3 AXL
9	ovulation cycle	GO:0042698	9.26	TYRO3 AXL
10	negative regulation of lymphocyte activation	GO:0051250	9.16	TYRO3 AXL
11	forebrain cell migration	GO:0021885	8.96	TYRO3 AXL
12	platelet activation	GO:0030168	8.92	TYRO3 FGA CD40LG AXL

Molecular functions related to Zika Fever according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	phosphatidylinositol 3-kinase binding	GO:0043548	8.96	TYRO3 AXL
2	virus receptor activity	GO:0001618	8.8	TYRO3 CD209 AXL

Sources

Sources for Zika Fever

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia